Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

被引：34

作者：

Kuppen, Malou C. P. ^{[1
]}

Westgeest, Hans M. ^{[2
]}

van der Doelen, Maarten J. ^{[3
]}

van den Eertwegh, Alphonsus J. M. ^{[4
]}

Coenen, Jules L. L. M. ^{[5
]}

Aben, Katja K. H. ^{[6
,7
]}

van den Bergh, Alphons C. M. ^{[8
]}

Bergman, Andries M. ^{[9
]}

van den Bosch, Joan ^{[10
]}

Celik, Filiz ^{[11
]}

Hendriks, Mathijs P. ^{[12
]}

Lavalaye, Jules ^{[13
]}

van der Meer, Saskia ^{[14
]}

Polee, Marco B. ^{[15
]}

Somford, Diederik M. ^{[16
]}

van Oort, Inge M. ^{[17
]}

Uyl-de Groot, Carin A. ^{[1
]}

Gerritsen, Winald R. ^{[3
]}

机构：

[1] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Inst Med Technol Assessment, Rotterdam, Netherlands

[2] Amphia Hosp, Dept Internal Med, Breda, Netherlands

[3] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Nijmegen, Netherlands

[4] Vrije Univ, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam UMC, Amsterdam, Netherlands

[5] Isala, Dept Oncol, Zwolle, Netherlands

[6] Radboud Univ Nijmegen, Dept Hlth Evidence, Med Ctr, Nijmegen, Netherlands

[7] Netherlands Comprehens Canc Org, Utrecht, Netherlands

[8] Univ Med Ctr Groningen, Dept Radiat Oncol, Groningen, Netherlands

[9] Netherlands Canc Inst, Div Internal Med MOD & Oncogen, Antoni van Leeuwenhoek Hosp, Amsterdam, Netherlands

[10] Albert Schweitzer Ziekenhuis, Dept Internal Med, Dordrecht, Netherlands

[11] Deventer Hosp, Dept Nucl Med, Deventer, Netherlands

[12] Northwest Clin, Dept Internal Med, Alkmaar, Netherlands

[13] St Antonius Hosp, Dept Nucl Med, Nieuwegein, Netherlands

[14] Jeroen Bosch Hosp, Dept Urol, sHertogenbosch, Netherlands

[15] Med Ctr Leeuwarden, Dept Internal Med, Leeuwarden, Netherlands

[16] Canisius Wilhelmina Hosp, Dept Urol, Nijmegen, Netherlands

[17] Radboud Univ Nijmegen, Dept Urol, Med Ctr, Nijmegen, Netherlands

来源：

FUTURE ONCOLOGY | 2020年 / 16卷 / 19期

关键词：

metastatic castration-resistant prostate cancer; radium-223; real-world outcomes; sequencing; skeletal-related events; survival; BONE METASTASES; DOUBLE-BLIND; THERAPY; PHASE-3; TRIAL; RECOMMENDATIONS; EXPERIENCE; EFFICACY; EVENTS; CYCLES;

D O I：

10.2217/fon-2020-0039

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line >= 3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line >= 3 (HR: 3.267; 95% CI: 1.689-6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.

引用

页码：1371 / 1384

页数：14

共 32 条

[21] The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer [J].

Saad, Fred ;

Sternberg, Cora N. ;

Mulders, Peter F. A. ;

Niepel, Daniela ;

Tombal, Bertrand F. .

CANCER TREATMENT REVIEWS, 2018, 68 :25-37

[22] Analysis of overall survival by number of radium-223 injections received in an international expanded access program (lEAP). [J].

Saad, Fred ;

Keizman, Daniel ;

O'Sullivan, Joe M. ;

Carles, Joan ;

Wirth, Manfred ;

Gillessen, Silke ;

Thellenberg-Karlsson, Camilla ;

Miller, Kurt ;

Tucci, Marcello ;

Paganelli, Giovanni ;

Procopio, Giuseppe ;

Gratt, Jeremy ;

Seger, Monica ;

Nilsson, Sten ;

Heinrich, Daniel .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[23] An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223 [J].

Sartor, O. ;

Coleman, R. E. ;

Nilsson, S. ;

Heinrich, D. ;

Helle, S. I. ;

O'Sullivan, J. M. ;

Vogelzang, N. J. ;

Bruland, O. ;

Kobina, S. ;

Wilhelm, S. ;

Xu, L. ;

Shan, M. ;

Kattan, M. W. ;

Parker, C. .

ANNALS OF ONCOLOGY, 2017, 28 (05) :1090-1097

[24] Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First US Experience from an Expanded Access Program [J].

Sartor, Oliver ;

Vogelzang, Nicholas J. ;

Sweeney, Christopher ;

Fernandez, Daniel C. ;

Almeida, Fabio ;

Iagaru, Andrei ;

Brown, Alan, Jr. ;

Smith, Matthew R. ;

Agrawal, Manish ;

Dicker, Adam P. ;

Garcia, Jorge A. ;

Lutzky, Jose ;

Wong, Yu-Ning ;

Petrenciuc, Oana ;

Gratt, Jeremy ;

Shore, Neal D. ;

Morris, Michael J. .

ONCOLOGIST, 2018, 23 (02) :193-202

[25] Metastatic Prostate Cancer [J].

Sartor, Oliver ;

de Bono, Johann S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (07) :645-657

[26] Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial [J].

Sartor, Oliver ;

Coleman, Robert ;

Nilsson, Sten ;

Heinrich, Daniel ;

Helle, Svein I. ;

O'Sullivan, Joe M. ;

Fossa, Sophie D. ;

Chodacki, Ales ;

Wiechno, Pawel ;

Logue, John ;

Widmark, Anders ;

Johannessen, Dag Clement ;

Hoskin, Peter ;

James, Nicholas D. ;

Solberg, Arne ;

Syndikus, Isabel ;

Vogelzang, Nicholas J. ;

O'Bryan-Tear, C. Gillies ;

Shan, Minghua ;

Bruland, Oyvind S. ;

Parker, Christopher .

LANCET ONCOLOGY, 2014, 15 (07) :738-746

[27] Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 [J].

Scher, Howard I. ;

Morris, Michael J. ;

Stadler, Walter M. ;

Higano, Celestia ;

Basch, Ethan ;

Fizazi, Karim ;

Antonarakis, Emmanuel S. ;

Beer, Tomasz M. ;

Carducci, Michael A. ;

Chi, Kim N. ;

Corn, Paul G. ;

de Bono, Johann S. ;

Dreicer, Robert ;

George, Daniel J. ;

Heath, Elisabeth I. ;

Hussain, Maha ;

Kelly, Wm. Kevin ;

Liu, Glenn ;

Logothetis, Christopher ;

Nanus, David ;

Stein, Mark N. ;

Rathkopf, Dana E. ;

Slovin, Susan F. ;

Ryan, Charles J. ;

Sartor, Oliver ;

Small, Eric J. ;

Smith, Matthew Raymond ;

Sternberg, Cora N. ;

Taplin, Mary-Ellen ;

Wilding, George ;

Nelson, Peter S. ;

Schwartz, Lawrence H. ;

Halabi, Susan ;

Kantoff, Philip W. ;

Armstrong, Andrew J. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (12) :1402-+

[28] Parameters Associated With 6 Cycles of Radium-223 Dichloride Therapy in Metastatic Castrate-Resistant Prostate Cancer [J].

Stolten, M. D. ;

Steinberger, A. E. ;

Cotogno, P. M. ;

Ledet, E. M. ;

Lewis, B. E. ;

Sartor, O. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03) :E196-E196

[29] Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives [J].

van der Doelen, Maarten J. ;

Mehra, Niven ;

Hermsen, Rick ;

Janssen, Marcel J. R. ;

Gerritsen, Winald R. ;

van Oort, Inge M. .

CLINICAL GENITOURINARY CANCER, 2019, 17 (02) :79-87

[30] 223Ra Therapy in Patients With Advanced Castration-Resistant Prostate Cancer With Bone Metastases: Lessons from Daily Practice [J].

van der Doelen, Maarten J. ;

Kuppen, Malou C. P. ;

Jonker, Marianne A. ;

Mehra, Niven ;

Janssen, Marcel J. R. ;

van Oort, Inge M. ;

Gerritsen, Winald R. .

CLINICAL NUCLEAR MEDICINE, 2018, 43 (01) :9-16

← 1 2 3 4 →